Mercator MedSystems specializes in innovative medical technologies, particularly focusing on the Bullfrog Micro-Infusion Device Platform. This platform enables local micro-infusion, which is a method for delivering drugs and biologics directly across vessel walls in an interventional angiographic lab setting. By facilitating targeted delivery, this technology enhances the efficiency of therapeutic interventions while minimizing off-target effects commonly associated with systemic drug delivery. The Bullfrog device is designed to improve the precision of treatment for various conditions, including deep vein thrombosis (DVT) and below-the-knee restenosis, by ensuring that the therapeutic payload is delivered directly to the areas of interest.

The company is currently conducting clinical trials, notably the DEXTERITY trials, which aim to evaluate the effectiveness of local anti-inflammatory steroid delivery in improving outcomes for patients with DVT. These trials are particularly focused on reducing the chronic negative outcomes associated with local inflammation in the pelvis and thigh regions. The DEXTERITY-AFP and -SCI trials have received regulatory approvals from the FDA, UK MHRA, and Irish HPRA, underscoring the potential of Mercator MedSystems' technologies to advance treatment options and improve patient outcomes in vascular health.

United States

Mercator MedSystems, Inc., is a medical technology company focused on the treatment of peripheral artery disease utilizing its catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel. The Company’s technology also enables the commercialization of novel therapeutics for other vascular diseases, hypertension, oncology, and regenerative medicine.

Mercator MedSystems

Company Details